Obermatt
See Similar Stocks →

Flags

Financial distress

AbbVie

NYQ:ABBV · US00287Y1091
BiotechnologyXX-Large

360

46
EV / EBIT65
Price / Owner Earnings16
Owner Earnings Yield60
Dividend Yield100
Price/Sales51
EV / Gross Profit51
Price/Book1
Return on Capital96
Cash Return on Capital78
EBIT Margin84
Gross Profitability67
Cash Conversion96
Accruals60
Owner Earnings Margin60
Sales growth44
Profit Growth100
Long-Term EPS Growth61
Owner Earnings Growth39
Reinvestment60
Price momentum42
Debt load5
Refinancing35
Debt Payback12
Liquidity78
Analyst ratings15
Opinion Changes50
Price Target Upside27
Market mood71
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

AbbVie clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeXX-Large
TypePublic Company
ExchangeNYSE
Founded2012
Employees48,915
Websiteabbvie.com
ISINUS00287Y1091
Last UpdateApr 2, 2026
Indices
S&P 500 (USA)D.J. US Health Care
Themes
NeurologyHematologyPain ManagementChronic DiseasesImmunologyOphthalmologyCentral Nervous SystemInflammationRheumatologyOncologyGastroenterologyPsychiatryBiotechnologyHealth CareMedicalPharmaceutical

Description

AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization, and sale of innovative medicines and the…

Analysis

Quality compounder

AbbVie Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is expensive. You pay 38.0× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 15% yearly growth; analysts expect 15%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is stretched. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
45
20252026

All-time high

75

Jan 2025

All-time low

42

Mar 2026

Average rank

54

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
51
28
—
—
Price/Earnings
17
61
—
—
Price/Book
1
1
—
—
Dividend Yield
100
100
—
—
Value (overall)
44
72
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare AbbVie with its peers
Enanta Pharmaceuticals
NSQ:ENTA
62
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Legend Biotech
NSQ:LEGN
30
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Ironwood Pharmaceuticals
NSQ:IRWD
92
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Xbiotech
NSQ:XBIT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ADMA Biologics
NMQ:ADMA
97
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
ArriVent BioPharma
NMQ:AVBP
89
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →